Nuga Medical Co., Ltd.

Nuga Medical Co., Ltd. specializes in ultrasound-guided biopsy devices. These include systems like the NM-7000, which is designed for broader procedural use, as well as specialized probes such as the N7-S, N5-1, and N6-DM-13-02-000-01A-10. These products are intended for precise tissue sampling during imaging-guided procedures, commonly used in oncology and other diagnostic fields.

Nuga Medical Co., Ltd. is based in South Korea. This means the company must comply with South Korea’s medical device regulations, as well as those of other markets where its devices are distributed, such as the EU and the US. The regulatory classifications and listings (e.g., EUDAMED and FDA’s 510(k)) reflect the device’s compliance requirements in those specific regions.

Nuga Medical Co., Ltd.’s devices are listed in the EUDAMED database and the FDA’s 510(k) registry. EUDAMED is the European Union’s transparency database for medical devices, ensuring traceability and compliance with EU regulations, while the FDA’s 510(k) registry confirms premarket clearance for devices marketed in the US under the FDA’s classification system. Listing in these databases demonstrates that the devices meet the regulatory standards of their respective markets.

Under EU regulations, Nuga Medical Co., Ltd.’s devices are classified as either Class II or Class IIa. This classification determines the level of scrutiny and regulatory requirements they must meet, such as clinical evaluations, conformity assessments, and post-market surveillance. In the US, the FDA’s 510(k) clearance process applies, which involves demonstrating substantial equivalence to a legally marketed predicate device. The classification ensures appropriate oversight based on the device’s risk level.